5 FDA decisions to watch in the first quarter
BioPharma
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® compared to epoetin alfa ...
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt) compared to epoetin alfaPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASH--Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension , today announced...
Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The